Lung cancer is considered the leading cause of cancer death in the word. Among all lung cancer cases,
non-small cell lung cancer (NSCLC) accounts for 85%. Currently, chemotherapy is still the major therapeutic
method of lung cancer. However, chemoresistance is a serious obstacle in treating NSCLC. Up to now, many
reports have suggested that microRNAs(miRNAs) could contribute to lung cancer cell chemosensitivity. MicroRNAs,
a class of endogenous non-coding small RNAs, regulate gene expression by binding to their complementary
target messenger RNAs, leading to mRNA degradation or translational suppression. Numerous studies
indicate that changes of specific miRNA expression may contribute to chemoresistance or chemosensitivity.
Consequently, targeting specific miRNAs could become an effective approach to predict the therapeutic effect of
different anticancer agents, achieve more effective personalised treatments and enhance chemosensitivity. This
review summarizes the several major drug resistance mechanisms and focuses on the roles of miRNAs in regulating
chemoresistance in NSCLC.
Keywords: MicroRNAs, chemotherapy, drug resistance, cisplatin, non-small cell lung cancer (NSCLC), chemosensitivity.
Rights & PermissionsPrintExport